Original Article

Multiparametric positron emission tomography/magnetic resonance imaging in nasopharyngeal carcinoma: Correlations between magnetic resonance imaging functional parameters and \(^{18}\)F-fluorodeoxyglucose positron emission tomography imaging biomarkers and their predictive value for treatment failure

Sheng-Chieh Chan*, Shu-Hang Ng*, Chih-Hua Yeh*, Kai-Ping Chang*

*Department of Nuclear Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Department of Diagnostic Radiology, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan

ABSTRACT

Objectives: The clinical significance of positron emission tomography/magnetic resonance imaging (PET/MRI) functional parameters in nasopharyngeal carcinoma (NPC) remains unclear. The purpose of this prospective study was two-fold: (1) to investigate the associations between simultaneously acquired PET/MRI perfusion, diffusion, and glucose metabolism parameters in patients with NPC and (2) to analyze their predictive value with respect to treatment failure. Materials and Methods: We enrolled 85 patients with primary NPC who simultaneously underwent \(^{18}\)F-fluorodeoxyglucose PET/CT and PET/MRI before definitive treatment. The following variables were determined: (1) functional parameters from the MRI component, including perfusion values (\(K^\text{trans}\), \(k_p\), \(v_e\), and initial area under the enhancement curve) and apparent diffusion coefficient (ADC) values, and (2) PET parameters, including metabolic tumor volume (MTV). The reciprocal interrelationships between these parameters and their correlations with treatment failure were examined. Results: We observed significant negative associations between \(K^\text{trans}\) and ADC \((r = -0.215, P = 0.049)\) as well as between \(v_e\) and ADC \((r = -0.22, P = 0.04)\). Correlations between PET and MRI functional parameters were not statistically significant. Treatment failures were observed in 21.2% of patients without distant metastases. Multivariate analysis identified \(v_e\) as a significant independent predictor for treatment failure \((P = 0.022)\), whereas MTV showed a borderline significance \((P = 0.095)\). Patients in whom both \(v_e\) and MTV values were increased had a significantly higher rate of treatment failure (62.5%) than those with either one (21.9%) or no (7.7%) increased parameter \((P = 0.004)\). Conclusion: Correlation analyses revealed complex interrelationships among PET and MRI indices measured in patients with NPC. These parameters may have a complementary role in predicting treatment failure in this clinical setting.

KEYWORDS: DCE-MRI, Diffusion-weighted MRI, Nasopharyngeal carcinoma, Positron emission tomography/magnetic resonance imaging, Prognosis

INTRODUCTION

Nasopharyngeal carcinoma (NPC) differs significantly from other head and neck squamous cell carcinomas (HNSCCs) in terms of histological characteristics, treatment strategies, and clinical course [1]. There is also a distinctive geographic distribution of this malignancy in Southeast Asia and Northeastern Africa [1]. Despite recent advances in the field of radiotherapy or chemoradiotherapy, the survival of patients with NPC remains suboptimal [2].

Both magnetic resonance imaging (MRI) and \(^{18}\)F-fluorodeoxyglucose positron emission tomography/computed tomography (\(^{18}\)F-FDG-PET/CT) are currently part of...
the staging workup of NPC [1,3]. Besides anatomic information, MRI allows performing functional imaging, including the analysis of tumor perfusion with dynamic contrast-enhanced MRI (DCE-MRI) and the assessment of tumor cellularity using diffusion-weighted imaging (DWI).

A recent study demonstrated that DCE-MRI-derived perfusion parameters may predict treatment response in patients with NPC treated with neoadjuvant chemoradiotherapy [4]. In addition, it has been previously shown that a high pre-treatment apparent diffusion coefficient (ADC) on DWI is associated with a poor response to treatment and unfavorable posttherapeutic survival figures in different solid malignancies, including NPC [5] and breast cancer [6]. The ability of 18F-FDG PET/CT to predict treatment response and clinical outcomes in patients with NPC has been consistently demonstrated [7,8].

Different tumor characteristics (e.g., perfusion, cellularity, and glucose metabolism) are characterized by complex interrelationships, which, if understood in greater detail, can inform treatment planning and improve prognostic stratification. Integrated PET/MRI allows the simultaneous assessment of both PET glucose metabolism and MRI parameters of tumor perfusion/cellularity. The application of 18F-FDG PET/MRI for NPC staging is clinically feasible [9]. Cheng et al. [10] have also described the association between PET/CT and PET/MRI parameters. However, PET/MRI in their study [10] was obtained by the fusion of images from separate PET and MRI machines. In a small-sized study conducted in patients with NPC (n = 21), Cao et al. [11] have previously explored the feasibility of multiparametric imaging using an integrated PET/MRI scanner. However, the question as to whether these parameters can have prognostic significance in patients with NPC remains open.

In this scenario, the purpose of this prospective study was two-fold: (1) to investigate the associations between simultaneously acquired PET/MRI perfusion, diffusion, and glucose metabolism parameters in patients with NPC and (2) to analyze their predictive value with respect to treatment failure.

**MATERIALS AND METHODS**

**Ethics statements**

The study protocol complied with the tenets of the Helsinki Declaration. Ethical approval was granted by the Institutional Review Board of Chang Gung Memorial Hospital (IRB no. 103-7498A3) and all participants provided their written informed consent.

**Study patients and clinical management**

Patients with a histological diagnosis of primary NPC, no contraindications to MRI, and serum glucose levels <150 mg/dL before 18F-FDG PET/CT imaging were deemed eligible. Exclusion criteria were renal failure, claustrophobia, or other general contraindications to MRI.

On the same day, all of the study participants underwent 18F-FDG PET/CT followed by whole-body 18F-FDG PET/MRI. Patients with Stage I disease received definitive radiation therapy alone, whereas those with Stage II–IVB disease were treated with concurrent chemoradiotherapy. Standard platinum-based chemotherapy was administered to patients with metastatic disease [12,13].

Supplementary Figure 1 depicts the flow of patients through the study. Between October 2015 and May 2017, we identified 104 potentially eligible patients with primary NPC. Of them, four were excluded because they met at least one exclusion criteria. The remaining 100 patients underwent both 18F-FDG PET/CT and 18F-FDG PET/MRI imaging using the DWI and DCE-MRI protocols. The mean time interval between the scans was 61 min. Fifteen patients had MRI data not assessable either because of prominent motion artifacts or the presence of small-sized tumors. Consequently, the final study sample consisted of 85 patients [Table 1].

**18F-fluorodeoxyglucose positron emission tomography/computed tomography**

Patients were required to fast for at least 6 h before 18F-FDG PET/CT imaging on a Biograph mCT scanner (Siemens Medical Solutions, Malvern, PA, USA), which comprises a four-ring PET scanner and a 40-section CT scanner. Between 50 and 70 min after injection of 18F-FDG (370 MBq), PET emission images were obtained from the vertex to the mid-thigh. The scanning time per table position was 1.5 min, and a 200 × 200 matrix size was used. Before PET acquisition, patients underwent a standard helical CT imaging (from the head to the proximal thigh) using the manufacturer-supplied dose reduction software CareKV and CareDose 4D. The

| Table 1: General characteristics of the study patients (n=85) |
|-----------------|-------|
| Characteristic  | n     |
| Sex             |       |
| Male            | 61    |
| Female          | 24    |
| Age (years), mean±SD | 51±13 |
| T status        |       |
| T1              | 17    |
| T2              | 16    |
| T3              | 27    |
| T4              | 25    |
| N status        |       |
| N0              | 8     |
| N1              | 38    |
| N2              | 17    |
| N3              | 22    |
| M status        |       |
| M0              | 76    |
| M1              | 9     |
| AJCC/UICC stage (7th ed.ition) |       |
| I               | 3     |
| II              | 17    |
| III             | 23    |
| IV              | 42    |
| Cell type       |       |
| WHO I           | 1     |
| WHO II          | 13    |
| WHO III         | 71    |

AJCC: American Joint Committee on Cancer, UICC: Union for International Cancer Control, WHO: World Health Organization
following parameters were used: preset, 120 kV; collimation, 40 × 0.6 mm; pitch, 1.5; slice thickness, 2 mm. No intravenous iodinated contrast agents were administered. PET images were reconstructed with CT data for attenuation correction using an ordered-subset expectation maximization iterative reconstruction algorithm (2 iterations, 21 subsets).

**18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging**

Upon PET/CT completion, PET/MRI was performed on an integrated PET/MRI scanner (Biograph mMR, Siemens Healthcare, Erlangen, Germany), which simultaneously acquires PET and MRI data using a 3.0-T magnet. The examination protocol consisted of a whole-body scan followed by a detailed examination of the head and neck area [Supplementary Table 1]. We initially acquired a fast-view T1-weighted MRI localizer sequence for scout imaging and a Dixon volumetric interpolated breath-hold examination (VIBE) sequence for attenuation correction. Subsequently, a whole-body PET scan was performed from the head to the proximal thigh in four-bed positions (acquisition time per bed position: 4 min). During PET data acquisition, whole-body MRI was conducted simultaneously (for the corresponding four bed positions) using an axial breath-holding half-Fourier single-shot turbo spin echo (TSE) sequence and a sagittal short tau inversion recovery sequence.

Thereafter, regional head and neck PET and MRI images were obtained simultaneously. PET was performed with an acquisition time of 10 min, whereas MRI was acquired in the axial and coronal projections with a T1-weighted TSE sequence and a T2-weighted TSE sequence with fat saturation. Regional DWI was acquired using single-shot spin-echo echo-planar imaging with the modified Stejskal–Tanner diffusion gradient pulsing scheme. Coverage and image slicing were identical for T1- and T2-weighted images. Motion-probing gradients (b-value: 800 s/mm²) were applied along three orthogonal directions.

DCE-MRI of the head and neck region was subsequently acquired using a three-dimensional T1-weighted spoiled gradient-echo sequence. Before administration of the contrast agent, baseline longitudinal relaxation time (T1) values were calculated from the acquired images with the application of different flip angles (4°, 8°, 15°, and 25°). Dynamic series were obtained using the same sequence (flip angle: 15°) after the intravenous administration of a paramagnetic contrast agent (injection rate: 3 mL/s). Dedicated regional MRI imaging of the head and neck was carried out using a T1-weighted TSE sequence with fat saturation in the axial and coronal projections. We finally performed a whole-body axial VIBE with fat saturation. PET data were reconstructed using an ordinary Poisson ordered subset expectation maximization, with three iterations, 21 subsets, and a 4-mm Gaussian postprocessing filter into 344 × 344 matrices.

**Image analysis**

DCE-MRI images were transferred onto a postprocessing workstation and were analyzed using dedicated software (TISSUE 4D, Siemens Medical Systems, Erlangen, Germany). After motion correction and registration of pre- and postcontrast acquisitions, T1 mapping was generated automatically. Freehand regions of interest (ROIs) were manually drawn by an experienced head and neck radiologist in the primary tumor area. The software allows the implementation of a population-based approach for arterial input function, which was scaled in relation to the gadolinium dose and modeled with the biexponential model proposed by Tofts et al. and Kermode [14]. The pharmacokinetic parameters $K^\text{trans}$, $K_v$, and $K_r$, and initial area under the enhancement curve (iAUC) were subsequently calculated. In the two-compartment model, the volume transfer constant ($K^\text{trans}$) reflects the efflux rate of the contrast medium from blood plasma into the interstitial space through the vessel wall. $v_e$ is a measure of extravascular-extra-cellular leakage space (ELS) volume. $K_v$ reflects the backward flux of the contrast medium from the ELS to the blood plasma. The iAUC is related to the volume of blood in the tissue of interest. In this study, IAUC refers to the initial area under the time-concentration curve defined over the first 60 s of postenhancement images. DWI-derived ADC values were measured on ADC maps by drawing the ROI on tumors. A senior head and neck radiologist performed the procedure with the aid of T2-weighted and contrast-enhanced T1-weighted images.

The PMOD software package (PMOD Technologies Ltd., Zurich, Switzerland) was used to calculate 18F-FDG PET parameters. All of the ROIs were manually drawn by an experienced nuclear medicine physician. Standardized uptake value (SUV) was determined using the following formula: $\text{SUV} = (\text{decay-corrected activity in kilobecquerels}/\text{injected FDG activity in kilobecquerels/body weight in grams})$. MTV was obtained from attenuation-corrected 18F-FDG PET images. Boundaries were drawn large enough to include the primary nasopharyngeal tumor. In keeping with previous methodology [8,12,15], we used a SUV cutoff value of 2.5 to automatically generate contour margins around the target and within the boundary. All of the voxels with SUV values >2.5 within the contour margin were considered to calculate the MTV. We also determined the mean SUV value within the contour margin. Finally, total lesion glycolysis (TLG) was calculated as follows: $\text{TLG} = \text{Mean SUV} \times \text{MTV}$.

**Follow-up schedule and identification of treatment failure**

Patients were followed every week during the course of treatment and then every 3 months for the first 2 years, every 4 months for the subsequent 2 years, and every 6 months thereafter. A conventional workup was performed 3 months after treatment completion and subsequently either on a yearly basis or when clinically indicated. A lesion suspected of being a treatment failure was subjected to endoscopic biopsy, ultrasound-guided fine-needle aspiration, or CT-guided biopsy. When a biopsy was unfeasible or yielded a negative result, the patient underwent a close clinical and imaging follow-up.

**Statistical analysis**

Patients were followed up until January 2019 or censored on the date of death. The associations between the study variables were investigated using the Pearson’s correlation coefficient, whereas the Chi-square test was used to analyze the relationships between different clinical and imaging
parameters and treatment failures. Continuous clinical and imaging variables were dichotomized according to their mean values. Independent predictors of treatment failures were identified using multivariate analysis. Statistical calculations were performed with the SPSS statistical package (version 21.0; SPSS Inc., Chicago, IL, USA). Two-tailed $P < 0.05$ was considered statistically significant.

**RESULTS**

**Correlation between different imaging parameters**

The values of PET and MRI imaging parameters are shown in Supplementary Table 2. We found highly significant positive correlations between SUV, MTV, and TLG values measured on PET/CT and PET/MRI [$P < 0.001$, Supplementary Table 3]. As far as PET/MRI parameters are concerned, there were significant positive correlations [Figure 1a and Table 2] between $K_\text{trans}$ and $k_e$ ($r = 0.907, P < 0.001$), $K_\text{trans}$ and $v_e$ ($r = 0.416, P < 0.001$), as well as $K_\text{trans}$ and iAUC ($r = 0.601, P < 0.001$). Other significant positive correlations were those between $k_e$ and $v_e$, $k_e$ and iAUC, as well as $v_e$ and iAUC. Conversely, significant inverse correlations were evident between $K_\text{trans}$ and ADC ($r = -0.215, P = 0.049$, Figure 1b) as well as $v_e$ and ADC ($r = -0.22, P = 0.049$). DCE-MRI parameters and ADC did not show any significant correlation with SUV, MTV, or TLG [Figure 1c].

![Figure 1: Correlations between different PET/MRI functional parameters. Scatter diagrams showing the distribution of PET/MRI $K_\text{trans}$ in relation to $k_e$ (panel a), ADC (panel b), and SUV$_\text{max}$ (panel c). PET/MRI: Positron emission tomography/magnetic resonance imaging, ADC: Apparent diffusion coefficient, SUV$_\text{max}$: Maximum standardized uptake volume.](image)

**Table 2: Correlation analysis of different dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted imaging, and 18F-fluorodeoxyglucose positron emission tomography parameters measured on positron emission tomography/magnetic resonance imaging**

| Parameter | $K_\text{trans}$ | $k_e$ | $v_e$ | iAUC | ADC |
|-----------|------------------|-------|-------|------|-----|
| SUV$_\text{max}$ | 0.121 (0.270) | 0.100 (0.361) | -0.011 (0.918) | 0.047 (0.671) | -0.063 (0.568) |
| MTV | 0.093 (0.398) | 0.083 (0.450) | 0.004 (0.972) | -0.001 (0.996) | 0.077 (0.481) |
| TLG | 0.127 (0.246) | 0.138 (0.208) | 0.003 (0.982) | 0.011 (0.917) | 0.013 (0.906) |
| $k_e$ | 0.907 (<0.001) | | | | |
| $v_e$ | 0.416 (<0.001) | 0.248 (0.022) | | | |
| iAUC | 0.601 (<0.001) | 0.435 (<0.001) | 0.516 (<0.001) | | |
| ADC | -0.215 (0.049) | -0.179 (0.101) | -0.220 (0.049) | -0.168 (0.125) |

SUV$_\text{max}$: Maximum standardized uptake volume, MTV: Metabolic tumor volume, TLG: Total lesion glycolysis, iAUC: Initial area under the enhancement curve, $K_\text{trans}$: Volume transfer constant, $k_e$: Flux rate constant, $v_e$: Extracellular volume ratio, ADC: Apparent diffusion coefficient
Prediction of treatment failure using positron emission tomography/magnetic resonance imaging functional parameters

PET/MRI functional parameters were analyzed in relation to treatment failure [Table 3]. Of the 76 patients without distant metastases, ten were lost to follow-up [Supplementary Figure 1]. Consequently, the analysis was conducted on 66 patients. Treatment failures were identified in 14 (21.2%) cases. Specifically, locoregional, distant, and both locoregional and distant failures were diagnosed in 4, 7, and 3 patients, respectively. Male sex (P = 0.006), T3-4 status (P = 0.016), N2-3 status (P = 0.032), and higher AJCC staging (P = 0.007) were significant predictors for treatment failures. MTV from PET and \( v_e \) from DCE-MRI were capable of distinguishing between patients who developed treatment failures from those who did not \( [P = 0.049 \text{ and } 0.045, \text{ respectively, Figure 2}] \). After allowance for potential confounders in multivariate analysis, \( v_e \) was retained in the model as the only significant independent predictor of treatment failure \( (P = 0.022, \text{ hazard ratio} = 6.495) \), whereas MTV showed a borderline significance \( (P = 0.095, \text{ hazard ratio} = 3.914) \). Patients with an increase in \( v_e \) and MTV had a significantly higher recurrence rate \( [62.5\%, 5/8; \text{ Figure 3}] \) than those with either one (21.9%, 7/32) or no (7.7%) increased parameter \( (P = 0.004) \). Two illustrative cases without and with treatment failures and their corresponding PET and MRI parametric images are shown in Figures 4 and 5.

The sensitivity, specificity, and area under curve (AUC) of \( v_e >296 \) and MTV >14 in the prediction of treatment failures were 64.29%, 65.38%, and 0.622 and 57.14%, 75%, and 0.640, respectively. Supplementary Table 4 shows the diagnostic properties of different imaging parameters.

Male sex \( (P = 0.026), \text{ N2-3 status} (P = 0.041) \), higher EBV DNA titer \( (P = 0.02) \), higher \( K_{\text{trans}} \) \( (P = 0.02) \), or \( k_{ep} \) \( (P = 0.013) \) were significant predictors for distant failures. After allowance for potential confounders in multivariate analysis, kep was retained in the model as the only significant independent predictor \( (P = 0.018) \).

**DISCUSSION**

The main findings of our study are as follows: (1) simultaneous \(^{18}\)F-FDG-PET/MRI is clinically feasible in patients with NPC, with indices of tumor perfusion, tissue metabolism, and cellularity being successfully acquired in this malignancy; (2) MRI perfusion parameters are correlated with the diffusion parameter ADC, but no significant correlation exists between PET and MRI parameters; and (3) \( v_e \) and MTV may serve as biomarkers of treatment failures. Taken together, our results indicate that different imaging biomarkers derived from simultaneously acquired PET/MRI may provide complementary information in the pathogenesis of NPC and in the prediction of treatment failures in patients with primary NPC. To our knowledge, this is the first report describing the prognostic utility of PET/MRI parameters in NPC.

ADC values are increasingly being used as a diagnostic adjunct in the imaging workup of patients with suspected malignancies \([16,17]\). Conversely, DCE-MRI has emerged as a valuable technique for investigating the properties of tissue microvasculature. Using a 3.0 T MRI scanner, Ni and Liu \([18]\) have reported negative correlations between ADC and DCE-MRI parameters \( (K_{\text{trans}}, k_{ep}, \text{ or } v_e) \) in 44 patients with NPC. In keeping with their findings, we identified a significant

| Variable | n (%) | Treatment failure | P |
|----------|-------|-------------------|---|
| Patient number | 66 | 14 | |
| Age (years) | | | |
| ≤50 | 31 (47) | 6 | 0.728 |
| >50 | 35 (53) | 8 | |
| Sex | | | |
| Female | 20 (30) | 0 | 0.006 |
| Male | 46 (79) | 14 | |
| Cell type | | | |
| WHO Type I | 2 (3) | 1 | 0.194 |
| WHO Type II | 8 (12) | 0 | |
| WHO Type III | 56 (85) | 13 | |
| T status | | | |
| T1-2 | 28 (42) | 2 | 0.016 |
| T3-4 | 38 (58) | 12 | |
| N status | | | |
| N0-1 | 40 (61) | 5 | 0.032 |
| N2-3 | 26 (39) | 9 | |
| AJCC/UICC stage | | | |
| Stage I-II | 18 (27) | 0 | 0.007 |
| Stage III-IVb | 48 (73) | 14 | |
| EBV DNA (copies/mL) | | | |
| ≤5700 | 53 (80) | 9 | 0.097 |
| >5700 | 13 (20) | 5 | |
| SUVmax (g/mL) | | | |
| ≤18.9 | 36 (55) | 6 | 0.322 |
| >18.9 | 30 (45) | 8 | |
| MTV (mL) | | | |
| ≤14 | 45 (68) | 6 | 0.049 |
| >14 | 21 (32) | 8 | |
| \( K_{\text{trans}} \times 10^3 \) (min\(^{-1}\)) | | | |
| ≤380 | 53 (80) | 9 | 0.128 |
| >380 | 13 (20) | 5 | |
| \( k_{ep} \times 10^3 \) (min\(^{-1}\)) | | | |
| ≤180 | 54 (52) | 9 | 0.111 |
| >180 | 12 (48) | 5 | |
| \( v_e \times 10^3 \) | | | |
| ≤296 | 39 (59) | 5 | 0.045 |
| >296 | 27 (41) | 9 | |
| iAUC (mm²/s) | | | |
| ≤1000 | 38 (58) | 8 | 0.971 |
| >1000 | 28 (42) | 6 | |
| ADC (mm²/s) | | | |
| ≤767 | 18 (27) | 2 | 0.318 |
| >767 | 48 (73) | 12 | |

WHO: World Health Organization, AJCC: American Joint Committee on Cancer, UICC: Union for International Cancer Control, EBV: Epstein-Barr virus, SUVmax: Maximum standardized uptake volume, MTV: Metabolic tumor volume, iAUC: Initial area under the enhancement curve, \( K_{\text{trans}} \): Volume transfer constant, \( K_{ep} \): Flux rate constant, \( v_e \): Extracellular volume ratio, ADC: Apparent diffusion coefficient.
negative association between ADC and $K_{trans}$ or $v_e$. These results may be explained by the higher cellularity, increased cellular size, and elevated microvessel density and permeability of malignant nasopharyngeal tissue.

Previous studies conducted in patients with cervical, lung, rectal, and breast malignancies have generally shown a significant inverse correlation between FDG metabolism and ADC [19-23]. However, some studies conducted in HNSCCs have failed to confirm this relationship [24-26]. As far as NPC is concerned, two recent investigations failed to identify a significant correlation between SUV and ADC [10,11]. In the current study, we found no association between ADC and SUV [$P = 0.568$, Table 2], confirming that these biomarkers are unrelated with each other in patients with NPC. ADC quantification is prone to variations caused by different lesion components, neoplasm size, field strength, and selection of b-values [27], ultimately resulting in inconsistent associations between ADC and SUV in different malignancies.

A limited number of studies examined the relationships between DCE-MRI and $^{18}$F-FDG PET indices. No correlation between glucose metabolic parameters and $K_{trans}$ or $v_e$ has been identified in patients with HNSCCs [28,29], a finding confirmed in our study focusing on NPC. In light of these results, PET and DCE-MRI parameters seem to be unrelated with each other.

The use of multiparametric PET/MRI imaging for predicting prognosis in patients with malignancies is gaining momentum. In a study conducted using separate PET/CT and MRI scanners, Ng et al. [30] demonstrated that $k_{ep}$, $v_e$, and SUV were independent predictors of survival in patients with hypopharyngeal or oropharyngeal carcinoma. Wong et al. [31] reported that changes in SUV, TLG, or MRI-derived $v_e$, $K_{trans}$, ADC from separate PET and MRI scanners are significant predictors of treatment response in patients with HNSCC [31]. These promising results notwithstanding, the clinical utility of multiparametric PET and MRI imaging remains unclear in NPC. In the current study, $v_e$ and MTV were associated with treatment failures in patients with primary NPC. MTV, which reflects the burden of tracer-avid tumor tissue, has been shown to predict disease recurrences in NPC and other HNSCCs [32-34]. $v_e$ is a parameter reflecting the amount of extravascular extracellular space. Most neoplasms are characterized by high $v_e$ values, which may serve as a proxy for tumor aggressiveness [35]. Previous reports have shown that $v_e$ is associated with prognosis and treatment outcomes in HNSCC [30,31] and colorectal cancer [36]. Moreover, Chin et al. [37] described a positive association between $v_e$ and the occurrence of early distant metastases in NPC. Our study, based on the use of integrated PET/MRI, further demonstrates that $v_e$ is a significant risk factor for tumor relapse in patients with NPC. Notably, the combined assessment of both MTV and $v_e$ may allow patients to be stratified into three distinct prognostic groups. Accordingly, we observed that the rate of treatment failure of subjects with a concomitant increase in both MTV and $v_e$ was markedly higher (62.5%) than that of patients with either one (21.9%) or no (7.7%) increased parameter. Patients characterized by an increased risk of tumor relapse (i.e., with concomitant increase in both MTV and $v_e$) may be suitable...
candidates to receive induction chemotherapy or more strict surveillance protocols in future clinical trials.

It is noteworthy that the vast majority of studies focusing on the utility of multimodality imaging in the prognostic stratification of patients with head and neck malignancies have been performed using separate PET and MRI scanners [30,31,37]. In this scenario, we believe that simultaneous integrated PET/MRI imaging can outperform separate scans in terms of patient acceptability and minimize the biological variation related to distinct systems.

With regard to the applications of PET/MRI in current clinical practice, Chan et al. [9] have previously compared the diagnostic performances of PET/MRI and PET/CT for staging of primary NPC. By increasing the conspicuity of morphologically subtle lesions, PET/MR imaging may map local tumor extension more precisely than PET/CT. Moreover, PET/MRI also has a higher accuracy in the assessment of regional nodal status and an increased positive predictive value for distant metastases. Compared with PET/CT, PET/MRI allows obtaining an accurate disease staging in a single step with an excellent imaging co-registration. However, PET/MRI is not without limitations, including a low availability, high costs, and a longer scan length.

Some limitations of our study merit comment. First, our research was a single-center investigation. Second, longer follow-up periods are required to identify reliable predictors of long-term survival. Third, the analytical model for DCE-MRI and DWI used in this study might not be applicable to all patients, especially in the presence of small-sized or cystic lesions.

**Conclusion**

Different correlations between PET/MRI functional parameters identified in our study indicate that NPC is characterized by complex interrelationships between indices of metabolism, perfusion, and cellularity. It is thus possible that these parameters reflect different facets of NPC pathogenesis. MTV measured on PET and v_e assessed by DCE-MRI were identified as predictors of treatment failures and their combination allowed patient stratification into three distinct prognostic groups. PET and MRI perfusion imaging biomarkers derived from PET/MRI may have a complementary role in predicting treatment failure in patients with primary NPC.

**Acknowledgments**

The authors are thankful to Jhih-Chao Yang for his help in PET data processing.

**Financial support and sponsorship**

This work was supported in part by the Taiwan Ministry of Science and Technology (grant NSC 104-2314-B-182A-084-MY3).
Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet 2016;387:1012-24.
2. O’Sullivan B. Nasopharynx cancer: Therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;69:S118-21.
3. Ng SH, Chan SC, Yen TC, Chang JT, Ko SF, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: Comparison with conventional imaging work-up. Eur J Nucl Med Mol Imaging 2009;36:12-22.
4. Zheng D, Yue Q, Ren W, Liu M, Zhang X, Lin H, et al. Early responses assessment of neoadjuvant chemotherapy in nasopharyngeal carcinoma by serial dynamic contrast-enhanced MR imaging. Magn Reson Imaging 2017;35:125-31.
5. Zhang Y, Liu X, Zhang Y, Li WF, Chen L, Mao YP, et al. Prognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: A retrospective study of 541 cases. Sci Rep 2015;5:12242.
6. Park SH, Moon WK, Cho N, Song JC, Chang JM, Park JA, et al. Diffusion-weighted MR imaging: Pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010;257:56-63.
7. Chan SC, Chang JT, Wang JM, Lin CY, Ng SH, Fan KH, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: The role of standardized uptake value. Oral Oncol 2009;45:52-8.
8. Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu Z, et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2010;136:883-9.
9. Chan SC, Yeh CH, Yen TC, Ng SH, Chang JT, Lin CY, et al. Clinical utility of simultaneous whole-body (18)F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2018;45:1297-308.
10. Cheng Y, Bai L, Shang J, Tang Y, Ling X, Guo B, et al. Preliminary clinical results for PET/MR compared with PET/CT in patients with nasopharyngeal carcinoma. Oncol Rep 2020;43:177-87.
11. Cao C, Yang P, Su Y, Niu T, Hu Q, Chen X. Feasibility of multiparametric imaging with PET/MR in nasopharyngeal carcinoma: A pilot study. Oral Oncol 2019;93:91-5.
12. Chan SC, Hsu CL, Yen TC, Ng SH, Liao CT, Wang HM. The role of 18F-FDG PET-CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol 2013;49:71-8.
13. Chang KP, Tsang NM, Liao CT, Hsu CL, Chung MJ, Lo CW, et al. Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma. J Nucl Med 2012;53:21-8.
14. Tofts PS, Berkowitz B, Schnall MD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995;33:564-8.
15. Chen YH, Chang KP, Chu SC, Yen TC, Wang LY, Chang JT, et al. Value of early evaluation of treatment response using (18)F-FDG PET/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2019;46:650-60.
16. Kim JK, Kim KA, Park BW, Kim N, Cho KS. Feasibility of
24. Choi SH, Paeng JC, Sohn CH, Pagsisihan JR, Kim YJ, Kim KG, et al. Correlation of 18F-FDG uptake with apparent diffusion coefficient ratio measured on standard and high b value diffusion MRI in head and neck cancer. J Nucl Med 2011;52:1056-62.

25. Fruhwald-Pallamar J, Czerny C, Mayerhoefer ME, Halpern BS, Eder-Czembirek C, Brunner M, et al. Functional imaging in head and neck squamous cell carcinoma: Correlation of PET/CT and diffusion-weighted imaging at 3 Tesla. Eur J Nucl Med Mol Imaging 2011;38:1009-19.

26. Varoquaux A, Rager O, Lovblad KO, Masterson K, Dulguerov P, Ratib O, et al. Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: Quantitative analysis of ADC and SUV. Eur J Nucl Med Mol Imaging 2013;40:842-52.

27. Connolly M, Srinivasan A. Diffusion-Weighted Imaging in Head and Neck Cancer: Technique, Limitations, and Applications. Magn Reson Imaging Clin N Am 2018;26:121-33.

28. Bisdas S, Seitz O, Middendorp M, Chambron-Pinho N, Bisdas T, Vogl TJ, et al. An exploratory pilot study into the association between microcirculatory parameters derived by MRI-based pharmacokinetic analysis and glucose utilization estimated by PET-CT imaging in head and neck cancer. Eur Radiol 2010;20:2358-66.

29. Jansen JF, Schlöder H, Lee NY, Stambuk HE, Wang Y, Fury MG, et al. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: Pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F] FDG-PET. Int J Radiat Oncol Biol Phys 2012;82:299-307.

30. Ng SH, Liao CT, Lin CY, Chan SC, Lin YC, Yen TC, et al. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and [18F]-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. Eur Radiol 2016;26:4162-72.

31. Wong KH, Panek R, Danloa A, Mcquaid D, Riddell A, Welsh LC, et al. Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer. Eur J Nucl Med Mol Imaging 2018;45:759-67.

32. Chan SC, Chang JT, Lin CY, Ng SH, Wang HM, Liao CT, et al. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: Predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun 2011;32:989-96.

33. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 2009;15:5861-8.

34. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;74:1335-41.

35. Benjaminsen IC, Brurberg KG, Ruud EB, Rofstad EK. Assessment of extravascular extracellular space fraction in human melanoma xenografts by DCE-MRI and kinetic modeling. Magn Reson Imaging 2008;26:160-70.

36. Koh TS, Ng QS, Thng CH, Kwek JW, Koziarski R, Goh V. Primary colorectal cancer: Use of kinetic modeling of dynamic contrast-enhanced CT data to predict clinical outcome. Radiology 2013;267:145-54.

37. Chin SC, Lin CY, Huang BS, Tsang NM, Fan KH, Ku YK, et al. Pretreatment dynamic contrast-enhanced MRI improves prediction of early distant metastases in patients with nasopharyngeal carcinoma. Medicine (Baltimore) 2016;95:e2567.
Supplementary Table 1: Magnetic resonance imaging sequences parameters used for positron emission tomography/magnetic resonance imaging

| Region     | Sequence     | TR   | TE   | ST   | FOV   | VS   | PAT | T     |
|------------|--------------|------|------|------|-------|------|-----|-------|
| Precontrast| Whole body   | 3.6  | 1.23 | 500  | 4.1×2.6×3.1 | 2   | 01:35 |
|            | Whole body   | 1000 | 84   | 6    | 1.5×1.2×6.0   | 2   | 03:00 |
|            | Whole body   | 3400 | 57   | 4    | 1.4×1.0×4.0   | 2   | 04:25 |
|            | Head/neck    | 3.6  | 1.23 | 500  | 4.1×2.6×3.1   | 2   | 00:19 |
|            | Head/neck    | 528  | 12   | 4    | 1.2×0.9×4.0   | 2   | 01:28 |
|            | Head/neck    | 4300 | 83   | 4    | 1.1×0.9×4.0   | 2   | 02:45 |
|            | Head/neck    | 580  | 11   | 4    | 0.9×0.8×4.0   | 2   | 01:32 |
|            | Head/neck    | 5730 | 87   | 4    | 0.8×0.6×4.0   | 2   | 03:11 |
|            | Head/neck    | 7300 | 62   | 5    | 2.0×2.0×5.0   | 2   | 2:48  |
| Postcontrast| Head/neck    | 3.73 | 1.16 | 5    | 2.0×2.0×5.0   | 2   | 05:04 |
|            | Head/neck    | 679  | 11   | 4    | 1.2×0.9×4.0   | 2   | 01:53 |
|            | Head/neck    | 520  | 9.7  | 4    | 0.8×0.6×4.0   | 2   | 02:14 |
|            | Whole body   | 4.56 | 1.95 | 3    | 1.9×1.4×3.0   | 2   | 01:12 |

TR: Repetition time (ms), TE: Echo time (ms), ST: SLICE thickness (mm), FOV: Field of view (mm), VS: Voxel size (mm), PAT: Parallel acquisition technique, T: Scanning time (min), VIBE: Volumetric interpolated breath-hold examination, AC: Attenuation correction, HASTE: Half-Fourier single-shot turbo spine echo, STIR: Short tau inversion recovery, TSE: Turbo spin echo, FS: Fat saturation, DWI: Diffusion-weighted imaging, DCE: Dynamic contrast-enhanced, MRI: Magnetic resonance imaging.

Supplementary Table 2: Values of different positron emission tomography and magnetic resonance imaging parameters measured in the study

| Parameter                  | Unit                 | Value           |
|---------------------------|----------------------|-----------------|
| PET/MRI SUV<sub>max</sub> | g/mL                 | 7.82±3.07       |
| PET/MRI SUV<sub>max</sub> | cm<sup>3</sup>       | 14.07±6.60      |
| PET/MRI TLG               | g/mL×cm<sup>3</sup>  | 131.1±228.25    |
| PET/CT SUV<sub>max</sub>  | g/mL                 | 7.92±3.03       |
| PET/CT MTV                | cm<sup>3</sup>       | 16.4±20.60      |
| PET/CT TLG                | g/mL×cm<sup>3</sup>  | 170.18±365.61   |
| k<sup>trans</sup> (×10<sup>3</sup>) | min<sup>−1</sup> | 348.55±575.80  |
| k<sub>e</sub> (×10<sup>3</sup>) | min<sup>−1</sup> | 161.57±211.08  |
| v<sub>e</sub> (×10<sup>3</sup>) | mm<sup>3</sup>/s   | 298.04±162.28  |
| iAUC                      | mm<sup>2</sup>/s     | 974.96±419.70   |
| ADC                       | mm<sup>2</sup>/s     | 805.04±361.20   |

Data are expressed as means±SDs. PET: Positron emission tomography, MRI: Magnetic resonance imaging, CT: Computed tomography, SUV<sub>max</sub>: Maximum standardized uptake value, MTV: Metabolic tumor volume, TLG: Total lesion glycolysis, iAUC: Initial area under the enhancement curve, k<sup>trans</sup>: Volume transfer constant, k<sub>e</sub>: Flux rate constant, v<sub>e</sub>: Extracellular volume ratio, ADC: Apparent diffusion coefficient, SDs: Standard deviations.
### Supplementary Table 3: Correlation analysis of positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography parameters

| Parameter | PET/MRI | PET/CT |
|-----------|----------|--------|
| **SUV<sub>max</sub>** | 1.000 | 0.908 (<0.001)  |
| **SUV<sub>mean</sub>** | 1.000 | 0.674 (<0.001)  |
| **MTV** | 0.602 (<0.001) | 0.602 (<0.001)  |
| **TLG** | 0.646 (<0.001) | 0.646 (<0.001)  |

Data are expressed as correlation coefficients (Pearson’s r) and corresponding P values in parentheses; r (P value). PET: Positron emission tomography, MRI: Magnetic resonance imaging, CT: Computed tomography, SUV: Standardized uptake value, SUV<sub>max</sub>: Maximum SUV, SUV<sub>mean</sub>: Mean SUV, MTV: Metabolic tumor volume, TLG: Total lesion glycolysis.

### Supplementary Table 4: Prediction rates of positron emission tomography/magnetic resonance imaging parameters for treatment failure

| Parameter               | Cutoff | Sensitivity | Specificity | PPV | NPV | AUC  |
|-------------------------|--------|-------------|-------------|-----|-----|------|
| **SUV<sub>max</sub>**  | 18.9   | 57.14       | 57.69       | 26.67 | 83.33 | 0.530 |
| **MTV**                 | 14     | 57.14       | 75.00       | 38.10 | 86.67 | 0.640 |
| **K<sup>trans</sup>** (×10<sup>3</sup>) | 380    | 35.71       | 84.62       | 38.46 | 83.02 | 0.567 |
| **k<sub>e</sub>** (×10<sup>3</sup>) | 180    | 35.71       | 86.54       | 41.67 | 83.33 | 0.501 |
| **v<sub>e</sub>** (×10<sup>3</sup>) | 296    | 64.29       | 65.38       | 33.33 | 87.18 | 0.622 |
| **iAUC**                | 1000   | 42.86       | 57.69       | 21.43 | 78.95 | 0.544 |
| **ADC**                | 767    | 85.71       | 30.77       | 25.00 | 88.89 | 0.582 |

SUV<sub>max</sub>: Maximum standardized uptake value, MTV: Metabolic tumor volume, iAUC: Initial area under the enhancement curve, K<sup>trans</sup>: Volume transfer constant, k<sub>e</sub>: Flux rate constant, v<sub>e</sub>: Extracellular volume ratio, ADC: Apparent diffusion coefficient, PPV: Positive predictive value, NPV: Negative predictive value, AUC: Area under curve.